Cardio3 to start Phase III with cell therapy for heart failure
This article was originally published in Scrip
Executive Summary
Cardio3 Biosciences will start Phase III testing in the next few weeks with its lead product candidate, a cell therapy for heart failure called C-Cure (C3BS-CQR-1). The Mont-Saint-Guibert, Belgium-based biotech is also in the midst of raising a series D financing, and hopes to bring in about €30 million by the end of the year.